Latest news with #ZellunaASA
Yahoo
03-07-2025
- Business
- Yahoo
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the 'Company', OSE ticker 'ZLNA') to grant new shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to issue share options to all employees in the Company. A total of 1,634,000 options for shares in the Company have been distributed amongst the employees and two board members. The number of options granted corresponds to 8.0% of the outstanding number of shares in the Company. The combined number of options granted under both the previous and current share option programs corresponds to 8.7% of the outstanding shares. Each option gives the right to acquire one share in the Company. The options are granted without consideration. Pursuant to the vesting schedule for employees, 33% of the options will vest one year after the day of grant, 33% of the options will vest two years after the day of grant and the remaining 33% will vest three years after the day of grant (vesting is dependent on the option holder still being employed in the Company). For the board members, all options vest after 1 year. The exercise price has been set at NOK 13.34 per share, which corresponds to the volume-weighted average price over the past 30 calendar days. Options that are not exercised within 7 years from the date of grant will lapse and become void. Primary insiders in Zelluna ASA have received the following option grants, on the terms described above: Chief Executive Officer, Namir Hassan, has been granted 550,000 share options. Chief Financial Officer, Hans Vassgård Eid, has been granted 175,000 share options. All 23,398 options under the previous program have been terminated. Chief Operating Officer, Anders Holm, has been granted 145,000 share options. Head of Research, Luise Weigand, has been granted 145,000 share options. Head of CMC, Emilie Gauthy, has been granted 80,000 share options. Head of Clinical Operations, Øivind Foss, has been granted 70,000 share options. All 11,398 options under the previous program have been terminated. Head of Project Management, Julia Ino, has been granted 80,000 share options. Board Member, Bent Jakobsen, has been granted 96,000 share options. Board Member, Eva-Lotta Allan, has been granted 6,000 share options. For further information, please see or contact: Namir Hassan, CEO, Zelluna ASAEmail: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASAEmail: +47 482 48632
Yahoo
27-05-2025
- Business
- Yahoo
ZLNA – New registered share capital
Oslo, 27 May 2025: Zelluna ASA (the "Company") refers to the announcement on 24 May 2025 regarding a resolution by the Company's Board of Directors to issue 227,096 new shares in the Company against set-off of an option exercise fee. The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises, and the Company's new registered share capital is NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASA Email: +47 482 48632 About Zelluna ASAZelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off the shelf' T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off the shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off the shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-04-2025
- Business
- Yahoo
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025
Oslo, April 04, 2025, the Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 14:00 CET on April 29, 2025. The General Meeting will be held electronically. For participation, please log in at All documents regarding the Annual General Meeting are available at the Company's website: For further information, please contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: at@ +47 982 06 826 Namir Hassan, CEO, Zelluna ASAEmail: Phone: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASA Email: +47 482 48632 Attachments Notice of Annual General Meeting 2025 Appendix 1 - Registration and proxy form to the Annual General Meeting Appendix 2 - Annual Report 2024 Appendix 3 - Remuneration Guidelines 2025 Appendix 4 - Remuneration Report 2024 Appendix 5 - Recommendations by the Nomination Committee 2025Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
Zelluna ASA [ZLNA]: Annual Report 2024
Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2024. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. For further information, please contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: at@ +47 982 06 826 Namir Hassan, CEO, Zelluna ASAEmail: Phone: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASA Email: +47 482 48632 Attachments Zelluna Annual Report 2024 254900B4VALJZR9TL744-2024-12-31-0-enSign in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN
Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was resolved to carry out a reverse share split in the ratio 10:1. Radforsk Investeringsstiftelse has further agreed with the Company to make available, without any compensation a, necessary number of its existing shares to the Company to ensure that all fractions of shares are rounded up to the nearest whole share, thus avoiding that shareholders will have its shareholdings rounded off downwards. Please note the following key information in relation to the reverse share split: - Date on which the corporate action was made public: 19 December 2024 (notice of extraordinary general meeting)- Date of approval: 9 January 2025 (extraordinary general meeting held)- Reverse split ratio: Ten (10) old shares give one (1) new share - Last day including right: 31 March 2025 - Ex-date: 1 April 2025- Record date: 2 April 2025 In connection with the reverse share split, the Company's shares will be transferred to a new ISIN. Please note the following key information for the change of ISIN: - Issuer: Zelluna ASA - Previous ISIN: NO 001 0851603- New ISIN: NO 001 3524942- Date of ISIN change: 1 April 2025 For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASA Email: +47 482 48632 About Zelluna ASAZelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off the shelf' T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off the shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off the shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products.
